{
    "ticker": "PRTA",
    "name": "Prothena Corporation plc",
    "description": "Prothena Corporation plc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for diseases characterized by protein misfolding and amyloidosis. Founded in 2012 and headquartered in Dublin, Ireland, Prothena leverages its proprietary technology platform to develop therapies targeting neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The company is engaged in advancing its lead product candidate, PRX002, a monoclonal antibody designed to treat Parkinson's disease, which is in clinical trials. Prothena's innovative approach combines deep scientific expertise with a commitment to addressing unmet medical needs, aiming to transform the treatment landscape for patients suffering from debilitating conditions. With a robust pipeline of candidates and partnerships with leading pharmaceutical companies, Prothena is poised to make significant contributions to the field of neurology and beyond. The company's mission is to provide hope and improved outcomes for patients by developing safer and more effective therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Dublin, Ireland",
    "founded": "2012",
    "website": "https://www.prothena.com",
    "ceo": "Gene Kinney",
    "social_media": {
        "twitter": "https://twitter.com/ProthenaCorp",
        "linkedin": "https://www.linkedin.com/company/prothena-corporation-plc"
    },
    "investor_relations": "https://ir.prothena.com",
    "key_executives": [
        {
            "name": "Gene Kinney",
            "position": "CEO"
        },
        {
            "name": "Thomas J. Schall",
            "position": "Chairman"
        },
        {
            "name": "W. Scott Harkonen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PRX002",
                "PRX003"
            ]
        }
    ],
    "seo": {
        "meta_title": "Prothena Corporation plc | Innovative Immunotherapies",
        "meta_description": "Learn about Prothena Corporation plc, a biotechnology company focused on developing novel immunotherapies for neurodegenerative diseases. Discover our pipeline and commitment to patient care.",
        "keywords": [
            "Prothena",
            "Biotechnology",
            "Immunotherapy",
            "Neurodegenerative Diseases",
            "Alzheimer's Disease",
            "Parkinson's Disease"
        ]
    },
    "faq": [
        {
            "question": "What does Prothena specialize in?",
            "answer": "Prothena specializes in the discovery and development of novel immunotherapies for diseases caused by protein misfolding."
        },
        {
            "question": "Who is the CEO of Prothena?",
            "answer": "Gene Kinney is the CEO of Prothena Corporation plc."
        },
        {
            "question": "Where is Prothena headquartered?",
            "answer": "Prothena is headquartered in Dublin, Ireland."
        },
        {
            "question": "What are Prothena's main products?",
            "answer": "Prothena's main product candidates include PRX002 and PRX003, aimed at treating neurodegenerative diseases."
        },
        {
            "question": "When was Prothena founded?",
            "answer": "Prothena was founded in 2012."
        }
    ],
    "competitors": [
        "AMGN",
        "BIIB",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "NVAX",
        "MRNA",
        "GILD",
        "BMY"
    ]
}